表紙
市場調査レポート

若年性特発性関節炎(スティル病):パイプライン分析

Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 303578
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
若年性特発性関節炎(スティル病):パイプライン分析 Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015
出版日: 2015年10月30日 ページ情報: 英文 88 Pages
概要

スティル病は炎症性の疾患で、高い間欠熱や、サーモンピンク色の発疹の出現・消失、関節痛といった特徴があります。スティル熱は若年性関節リウマチ(JRA)の一種で、若年性突発性関節炎とも呼ばれています。主な症状には、食欲不振、吐き気、体重減少などがあります。また、リンパ腺が腫れあがったり、脾臓や肝臓が肥大化したり、喉が痛んだりする症状も一般に見られます。主な治療法には、抗炎症剤(非ステロイド系抗炎症性薬物(NSAID)やステロイド剤)などがあります。

当レポートでは、世界各国での若年性特発性関節炎(スティル病)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

若年性特発性関節炎(スティル病)の概要

治療薬の開発

  • 若年性特発性関節炎向けパイプライン製品:概要
  • 若年性特発性関節炎向けパイプライン製品:比較分析

各企業で開発中の若年性特発性関節炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

若年性特発性関節炎治療薬:開発中の製品の一覧(企業別)

若年性特発性関節炎治療薬の開発に従事している企業

  • Biocon Limited
  • Epirus Biopharmaceuticals, Inc.
  • Genor BioPharma Co., Ltd.
  • Hetero Drugs Limited
  • Mabion SA
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Oncodesign SA
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.

若年性特発性関節炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • adalimumabのバイオシミラー
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • anakinra (組み換え型)
  • certolizumab pegol
  • DNX-514
  • etanerceptのバイオシミラー
  • クローン病(炎症性腸疾患)向け RIP2 阻害薬
  • tocilizumabのバイオシミラー
  • tofacitinib

若年性特発性関節炎治療薬:パイプライン製品の最新動向

若年性特発性関節炎治療薬:休止中のプロジェクト

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7258IDB

Summary

Global Markets Direct's, 1'Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015', provides an overview of the Idiopathic Juvenile Arthritis (Still's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Juvenile Arthritis (Still's Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Idiopathic Juvenile Arthritis (Still's Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Idiopathic Juvenile Arthritis (Still's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Idiopathic Juvenile Arthritis (Still's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Juvenile Arthritis (Still's Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Idiopathic Juvenile Arthritis (Still's Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Juvenile Arthritis (Still's Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Overview
    • Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis
  • Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics under Development by Companies
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Idiopathic Juvenile Arthritis (Still's Disease) - Products under Development by Companies
  • Idiopathic Juvenile Arthritis (Still's Disease) - Companies Involved in Therapeutics Development
    • Biocon Limited
    • Epirus Biopharmaceuticals, Inc.
    • Genor BioPharma Co., Ltd.
    • Hetero Drugs Limited
    • Mabion SA
    • Mycenax Biotech Inc.
    • Oncobiologics, Inc.
    • Oncodesign SA
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sandoz International GmbH
    • Swedish Orphan Biovitrum AB
    • Therapeutic Proteins International, LLC
    • UCB S.A.
  • Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anakinra (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNX-514 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tofacitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Idiopathic Juvenile Arthritis (Still's Disease) - Recent Pipeline Updates
  • Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2015
  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Biocon Limited, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Genor BioPharma Co., Ltd., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Hetero Drugs Limited, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mabion SA, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mycenax Biotech Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Oncobiologics, Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Oncodesign SA, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Panacea Biotec Limited, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Pfizer Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Sandoz International GmbH, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Swedish Orphan Biovitrum AB, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Therapeutic Proteins International, LLC, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by UCB S.A., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics - Recent Pipeline Updates, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2015
  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top